MedTrace Logo

Effect of Thiamphenicol on EAAT2 and Other Biomarkers From Nasal Biopsied Tissue

NCT00958503 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-03-25

No results posted yet for this study

Summary

The purpose of this study is to determine if two-weeks of dosing with thiamphenicol is safe and is able to change the levels of certain pre-specified biomarkers in nervous tissue taken from the nasal passages.

Conditions

  • Healthy

Interventions

DRUG

Thiamphenicol

750 and 1500 mg/day;tablets

DRUG

Placebo

Matched tablets without active ingredient

Sponsors & Collaborators

  • SGS Life Sciences, a division of SGS Belgium NV

    collaborator OTHER

  • Psyadon Pharma

    lead INDUSTRY

Principal Investigators

  • Richard E Chipokin, PhD · Ruxton Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2007-09-30
Completion
2008-04-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00958503 on ClinicalTrials.gov